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Preoperative treatment 
of HER2-positive breast cancer
ABSTRACT
Preoperative chemotherapy is more and more frequently used in the treatment of localized and locally-advanced 
breast cancer. This approach not only creates optimal conditions for organ-sparing surgery but also provides us 
with valuable information on the biology and chemosensitivity of cancer. This data is then crucial for the choice 
of systemic adjuvant therapy. The availability of two anti-HER2 targeted agents (pertuzumab and trastuzumab) 
for the neoadjuvant treatment of breast cancer significantly improves the efficacy of this approach. Significantly 
increased percentage of patients experiencing complete pathological response correlates with improved out-
comes. This article is aimed at summarizing current knowledge regarding the role of pertuzumab in neoadjuvant 
treatment of HER2-positive breast cancer and comprises essential guidelines for the optimal use of currently 
reimbursed therapies in this disease.
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Introduction
After a long waiting period, on September 1, 2019 the 
Ministry of Health issued a positive decision regarding 
reimbursement of pertuzumab in the preoperative treat-
ment of patients with locally advanced HER2-positive 
breast cancer. The changes introduced into the drug 
program allow not only optimisation of safety but they 
also increase the effectiveness of neoadjuvant treatment. 
In contrast to the provisions of the drug program for pal-
liative treatment of patients with HER2-positive breast 
cancer, which, based on the results of CLEOPATRA 
study [1] strictly defined treatment regimen based on 
the combination of pertuzumab and trastuzumab, in 
preoperative management various treatment regimens 
including these drugs can be used. Expanding treatment 
options with new regimens is always, especially in the 
first period, associated with many doubts about the 
optimal combination of drugs, taking into account their 
safety and effectiveness. This article summarises the cur-
rent knowledge regarding the use of trastuzumab and 
pertuzumab in preoperative treatment, with particular 
emphasis on the possibility of using this drug in clinical 
practice in Poland. 
The role of preoperative treatment
Preoperative treatment is one of the options for 
the management of patients with early breast cancer. 
Despite a number of studies comparing the benefits of 
neoadjuvant versus adjuvant therapy, the advantage of 
preoperative treatment in relation to patient prognosis 
has not been demonstrated. The main goal of neoadju-
vant treatment is to increase the feasibility of surgical 
treatment in patients with initially inoperable, locally 
advanced tumour (IIIA–C and “inflammatory” breast 
cancer), in whom resection is impossible, or to create 
the possibility of breast-conserving surgery (BCS) in 
the case of primary operable tumours (T2 N0–1 M0). 
Preoperative chemotherapy allows an increase in the 
percentage of BSC procedures from a few to several 
per cent; however, in many patients, regardless of the 
response to systemic treatment, such a procedure cannot 
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be used due to the presence of objective contraindica-
tions. A recent meta-analysis comparing preoperative 
and postoperative treatment did not show differences 
according primary prognostic parameters. However, 
this analysis showed a significantly increased percentage 
of local recurrences in patients receiving preoperative 
treatment, which resulted from a much higher percent-
age of BCS procedures compared to patients who were 
undergoing primary surgical treatment [2]. 
Very important additional benefits associated with 
preoperative chemotherapy include early application of 
systemic treatment and obtaining information about the 
anti-tumour effect of the neoadjuvant treatment based 
on postoperative material examination. Confirmation 
of residual disease after preoperative treatment is an 
indication to consider adjuvant treatment with another 
cytotoxic drug (capecitabine in HER2-negative cancers 
or T-DM1 in HER2-positive cancers).
Pathological complete response
In modern clinical trials assessing different strate-
gies of preoperative chemotherapy, the pathological 
complete response (pCR) rate is the most commonly 
used primary endpoint. Unfortunately, for years, this 
parameter was not standardised, and in many studies, 
different research groups defined it differently; in some 
studies only the breast tumour was assessed, in others 
lymph nodes were also included, and sometimes pCR 
could be found even if carcinoma in situ or single inva-
sive cancer lesions were present [2]. The discrepancies 
in pCR definition between different studies make it very 
difficult to compare individual preoperative treatment 
strategies and perform meta-analyses that could clearly 
indicate the optimal neoadjuvant chemotherapy regimen. 
However, there is no doubt that the effectiveness of 
preoperative treatment depends primarily on the histo-
logical type of breast cancer. The expression of steroid 
receptors and a low proliferative index correlate with 
a lower probability of obtaining pCR (6.4% vs. 31% for 
luminal subtype A and the so-called “triple negative” can-
cer, respectively) [3]. Based on, among other things, the 
combined analysis of the German Breast Group (GBG) 
studies, it is known that patients achieving a complete 
pathological response (ypT0 ypN0) after preoperative 
chemotherapy have a very good prognosis regarding 
disease-free survival (DFS, HR = 4.04; P < 0.001) and 
overall survival (OS, HR = 7.39; P < 0.001). In the case 
of HER2-positive breast cancer, the probability of pCR 
depends on the use of molecularly targeted therapies. In 
the mentioned GBG analysis the pCR rate after the use 
of pre-operative chemotherapy in patients with luminal 
B HER2-negative and HER2-positive breast cancer was 
about 11%, while the combination of chemotherapy 
and trastuzumab doubled this percentage (to 22%). For 
HER2-positive, oestrogen receptor-negative (OR-nega-
tive) and progesterone receptor-negative (PR-negative) 
cancer, the pCR rates were 28% and 33% for chemothe-
rapy and combination chemotherapy with trastuzumab, 
respectively [3]. A meta-analysis involving more than 
11,000 breast cancer patients undergoing neoadjuvant 
treatment showed a significantly increased pCR rate after 
chemotherapy with trastuzumab (31–50%) compared to 
chemotherapy alone (18–30%) in the HER2-positive 
breast cancer population [4]. Furthermore, this study 
showed a strong relationship between pCR and prognosis 
in patients with HER2-positive/ER-negative/PR-negative 
breast cancer receiving trastuzumab in neoadjuvant the-
rapy (EFS, HR = 0.15, 95% CI 0.09–0.27; OS, HR = 0.08, 
95% CI 0.03–0.22).
Preoperative treatment 
of HER2-positive breast cancer
HER2 receptor overexpressed in breast cancer 
cells is one of the key mechanisms responsible for the 
high aggressiveness of the cancer, while being a critical 
therapeutic target. In 1998, trastuzumab (a monoclonal 
antibody that binds and inactivates HER2 receptor) was 
registered in the treatment of patients with metastatic 
breast cancer, and in 2006 the registered indications were 
expanded to include adjuvant treatment based on studies 
that showed a significant improvement of prognosis [5–7].
More than nine years ago, the first evidence re-
garding the efficacy and safety of preoperative chemo-
therapy combined with trastuzumab in patients with 
HER2-positive breast cancer was reported. Since then, 
several subsequent clinical trials have been conducted 
assessing various neoadjuvant chemotherapy regimens 
with trastuzumab. In the following years, with the 
advent of new anti-HER2 drugs active in generalised 
HER2-positive breast cancer (pertuzumab and lapat-
inib), assessment of the possibility of combining these 
drugs within neoadjuvant treatment was also started. 
The purpose of the combination of anti-HER2 drugs 
was to increase the likelihood of a response and improve 
safety (primarily to reduce the risk of cardiotoxicity) 
by reducing the intensity of chemotherapy included 
in preoperative treatment [8–11]. Table 1 summarises 
the studies assessing preoperative regimens containing 
anti-HER2 antibodies.
Combination of anti-HER2 drugs 
with anthracyclines
In some studies assessing the role of trastuzumab 
in preoperative treatment, it was used concomitantly 
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with anthracyclines, although this combination is associ-
ated with a high risk of myocardial insufficiency and is 
generally not recommended for adjuvant and palliative 
treatment. Despite this, in several studies (e.g. NOAH, 
GeparQuinto, ACOSOG Z1041, HannaH, or Cher-Lob) 
in which trastuzumab was associated with anthracy-
cline-containing regimens (a total of over 1000 patients), 
no clinically significant increase of cardiotoxicity risk was 
observed [14, 16, 19, 22]. There is no doubt, however, that 
patients participating in these trials were subject to very 
close cardiological monitoring, which is not a standard 
in routine clinical practice. Therefore, the use of preop-
erative chemotherapy regimens combining trastuzumab 
with anthracyclines is not recommended.
One of the reasons for combining anthracyclines 
with trastuzumab as part of preoperative treatment 
was an attempt to increase the effectiveness of classic 
neoadjuvant chemotherapy regimens, usually based 
on anthracyclines and taxoids. According to assump-
tions, concomitant use of trastuzumab with all cycles 
of preoperative chemotherapy should have been 
more effective than using this drug only during taxoid 
administration. However, the majority of studies on 
preoperative treatment of HER2-positive breast cancer 
patients did not allow conclusions to be drawn about 
the real benefits of concurrent use of trastuzumab 
and anthracyclines, because they did not compare two 
trastuzumab administration regimens in parallel. In 
the phase III ACOSOG Z1041 study, 282 patients with 
initially operable HER2-positive breast cancer were 
randomly assigned (1:1) to a sequential arm receiving 
the 4 × FEC → 12 × PXL 80 mg/m2 + trastuzumab or 
to a concurrent arm with the regimen 12 × PXL + tras-
tuzumab → 4 × FEC. No significant difference was seen 
in pCR rate (primary endpoint) between study arms; 
pCR was reported in 56.5% of patients in the sequen-
tial arm and 54.2% in the concurrent arm (OR = 0.90; 
95% CI 0.55–1.49). The deterioration of left ventricular 
function (G1–4 and G3–4 according to WHO CTC) was 
observed in 3.6% and 0% of patients in the sequential 
arm and 8.4% and 0.7% in the concurrent arm, respec-
tively [14]. The three-arm, phase II TRYPHAENA 
study compared in two arms concurrent or sequential 
use of FEC regimen with the combination of pertu-
Table 1. Summary of clinical studies evaluating trastuzumab in neoadjuvant treatment. P — paclitaxel, T — trastuzumab, 
A — doxorubicin, C — cyclophosphamide, D — docetaxel (D75 — 75 mg/m2 q3w, D100 — 100 mg/m2 q3w, D75/100 
— dose escalation possible), E — epirubicin, F — 5-fluorouracil, K — carboplatin, M — methotrexate, PER — pertuzumab
Study Number of 
patients
Regimen pCR Ref.
MDACC 23 4 × P + T  4 × FEC + T 65% [12]
NOAH 117 3 × AP + T  3 × P + T  3 × CMF + T 38% [11]
NeoALLTO 149 T  T + 12 × P 28% [13]
HannaH 299 4 × D75 + T  4 × FEC + T 34% [14]
GeparQuinto 309 4 × EC + T  4 × D100 + T 30% [15]
ACOSOG Z1041 140 4 × FEC  12 × P + T 48% [16]
142 12 × P + T  4 × FEC + T 47%
NSABP B-41 181 4 × AC  4 × P + T 49% [7]
REMAGUS 2 62 4 × EC  4 × D100 + T 26% [17]
GEICAM/2006-14 50 4 × EC  4 × D100 + T 48% [18]
CHER-LOB 36 12 × P + T  4 × FEC + T 25% [19]
PCH 29 12 × P + K + T 69% [20]
NeoSphere 107 4 × D(75/100) + T 29% [10]
107 4 × D(75/100) + PER + T 46%
107 4 × PER + T 17%
96 4 × D(75/100) + PER 24%
TRYPHAENA 72 3 × FEC + PER + T  3 × DXL(75/100) + PER + T 61% [11]
75 3 × FEC  3 × DXL(75/100) + PER + T 57%
76 6 × D75 + K + T + PER (TCHP) 66%
KRISTINE 221 6 × D75 + K + T + PER (TCHP) 56% [21]
223 T-DM1 + PER 44%
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zumab and trastuzumab (FEC + trastuzumab + per-
tuzumab → docetaxel + trastuzumab + pertuzumab 
vs. FEC → docetaxel + trastuzumab + pertuzumab) 
[11]. In this study, pCR rates were 51% in the concur-
rent arm and 45% in the sequential arm, but the risk 
of neutropaenic fever was clearly higher in the concur-
rent arm than in the sequential arm (18% vs. 9%) with 
comparable cardiotoxicity.
Optimal combination of pertuzumab 
with trastuzumab and chemotherapy 
in preoperative treatment
Compared to the number of clinical studies on the 
role of trastuzumab in the preoperative treatment of 
patients with HER2-positive breast cancer, the num-
ber of studies on the combination of trastuzumab with 
pertuzumab is significantly smaller. Many early studies 
on trastuzumab focused on the potential for reducing 
the intensity of chemotherapy by excluding anthra-
cyclines. A study conducted by Hurley et al. involved 
48 patients with locally advanced or inflammatory 
HER2-positive breast cancer. Preoperative treatment 
administered for 12 weeks (docetaxel 70 mg/m2 d. 1 
+ cisplatin 70 mg/m2 d. 1 + weekly trastuzumab — four 
courses in total) led to a pathological complete re-
sponse in 23% of patients [23]. Another study looked 
at the activity of combination of carboplatin at a dose 
of AUC6 + paclitaxel 80 mg/m2 and trastuzumab at 
a weekly dose during 12 weeks of preoperative treat-
ment in patients with operable (majority of patients) 
HER2-positive breast cancer. Pathological complete 
responses were observed in a surprisingly high percent-
age of patients (76%), which could be a consequence 
of enrolment of patients with small tumours [20]. In 
another phase II study of neoadjuvant chemotherapy 
without anthracycline, 56 patients with HER2-positive 
breast cancer (IIB–IIIC) were randomly assigned to 
two preoperative chemotherapy regimens based on the 
combination of trastuzumab, carboplatin, and paclitaxel 
(PXL 175 mg/m2 + carboplatin AUC6 + trastuzumab 
in a three-week schedule — a total of four courses or 
PXL 80 mg/m2 d. 1, 8, 15 + carboplatin AUC2 d. 1, 8, 
15 + trastuzumab on a weekly basis — four courses in 
total). In the weekly chemotherapy arm a significant 
increase of pCR rate, from 40.7% to 69% (HR = 0.3; 
95% CI 0.1–0.9), was observed, which was particu-
larly marked in patients with hormone-dependent and 
HER2-positive breast cancer — 67% vs. 21% (71% 
vs. 62% in ER-negative/PR-negative tumours) [24]. 
The percentage of side effects was similar in both arms.
A key study on the role of pertuzumab in preopera-
tive treatment (phase II NeoSphere study) [10] even 
allowed for complete abandonment of chemotherapy 
before surgery. In this study, 417 HER2-positive breast 
cancer patients were randomly assigned to preoperative 
treatment according to the schedules — (i) 4 × doce-
taxel + trastuzumab, (ii) 4 × docetaxel + trastuzum-
ab + pertuzumab, (iii) 4 × trastuzumab + pertuzumab, 
and (iv) 4 × docetaxel + pertuzumab. After surgery, all 
patients received anthracycline-based adjuvant therapy 
with trastuzumab for up to 12 months, and patients in 
the non-chemotherapy arm also received docetaxel. The 
NeoSphere study showed the highest pCR rate in the 
arm receiving a three-drug regimen (docetaxel + tras-
tuzumab + pertuzumab) — 46%, compared to 29% 
(docetaxel + trastuzumab), 24% (docetaxel + pertu-
zumab), and 17% (pertuzumab + trastuzumab). This 
study also showed no additional toxicity associated with 
the addition of pertuzumab. 
In the aforementioned TRYPHAENA study, in ad-
dition to anthracycline-containing regimens, the efficacy 
and safety of a docetaxel, carboplatin, and trastuzumab 
with pertuzumab regimen (TCHP) were also assessed. In 
this arm, a very high pCR rate of 64% was achieved at 
the expense of side effects such as febrile neutropaenia 
(17% of patients), G3 diarrhoea (12%), G3 anaemia 
(17%), and thrombocytopaenia (12%).
In the phase III KRISTINE study comparing the 
experimental regimen with trastuzumab emtansine 
(T-DM1) and pertuzumab versus TCHP in preoperative 
treatment, a high pCR rate of 55.7% was confirmed 
in the TCHP arm (221 patients) versus 44.4% in the 
experimental arm [21]. 
Regimens of preoperative chemotherapy 
in HER2-positive breast cancer
Trastuzumab s.c. — 600 mg s.c.; dosing every three 
weeks
Trastuzumab i.v. — 8 mg/kg (first loading dose) then 
6 mg/kg i.v.; dosing every three weeks
Pertuzumab — 840 mg i.v. (loading dose followed by 
420 mg i.v.) — every 3 week
AC → PTP
Four cycles — doxorubicin 60 mg/m2 i.v. + cyclophos-
phamide 600 mg/m2 i.v. d. 1 every three weeks, then
paclitaxel 80 mg/m2 i.v. d. 1 weekly for 12 weeks + tras-
tuzumab* + pertuzumab**
After surgery trastuzumab should be continued for up 
to a year.
AC → DTP
Four cycles — doxorubicin 60 mg/m2 i.v. + cyclophos-
phamide 600 mg/m2 i.v. d. 1 every three weeks, then
four cycles –— docetaxel 100 mg/m2* i.v. d. 1 every three 
weeks + trastuzumab* + pertuzumab**
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After surgery trastuzumab should be continued for up 
to a year.
EC → DTP
Four cycles — epirubicin 90 mg/m2 i.v. + cyclophospha-
mide 600 mg/m2 i.v. d. 1 every three weeks, then
four cycles — docetaxel 100 mg/m2* i.v. d. 1 every three 
weeks + trastuzumab*+ pertuzumab**
After surgery trastuzumab should be continued for up 
to a year.
EC → PTP 
Epirubicin 75 mg/m2 i.v. + cyclophosphamide 
500 mg/m2 i.v. d. 1 every three weeks, then
paclitaxel 80 mg/m2 i.v. weekly for 12 weeks + trastu-
zumab* + pertuzumab**
After surgery trastuzumab should be continued for up 
to a year.
TCHP
Six cycles — docetaxel 75 mg/m2 i.v. + carboplatin 
AUC6 i.v. + trastuzumab* + pertuzumab** 
After surgery trastuzumab should be continued for up 
to a year.
PCHP
Four cycles — paclitaxel 80 mg/m2 i.v. d. 1, 8, 15 + car-
boplatin AUC2 i.v. d. 1, 8, 15, concomitantly trastu-
zumab* + pertuzumab**
After surgery trastuzumab should be continued for up 
to a year.
Summary
The introduction of anti-HER2 drugs significantly 
improved the effectiveness of neoadjuvant treatment in 
HER2-positive breast cancer patients. Without a signifi-
cant increase in toxicity, it was possible to achieve a sig-
nificant increase in pCR rate and increase the percentage 
of patients undergoing breast-conserving surgery. The 
current changes in the “Breast Cancer Treatment” drug 
program finally allow us to offer patients with HER2-
-posi tive breast cancer effective and safe preoperative 
treatment in line with international standards in the case 
of local advancement (N+) or planned breast-conserving 
surgery in patients with a tumour of diameter > 2 cm. 
When applying preoperative treatment in patients with 
HER2-positive breast cancer, it should be remembered 
that the use of trastuzumab is not the only condition for 
obtaining the expected clinical benefits. The maximum 
effectiveness of neoadjuvant treatment is guaranteed by 
the use of an optimal combination of chemotherapy with 
anti-HER2 drugs and the maintenance of the originally 
planned dose intensity. It should also be remembered 
that the combination of trastuzumab and pertuzumab 
with docetaxel monotherapy (as in the NeoSphere study) 
is not a recommended preoperative treatment because 
of the need for use of anthracycline-containing adjuvant 
chemotherapy. The use of only the docetaxel + trastu-
zumab + pertuzumab combination not only reduces 
the likelihood of obtaining pCR, but also precludes or 
significantly delays postoperative use of trastuzumab. If 
there is any doubt about the tolerability of the planned 
treatment, alternative chemotherapy regimens (e.g. 
with lower cardiotoxic potential — anthracycline-free 
regimens) or showing a lower risk of myelosuppression 
(weekly regimens) should be considered. As in the case 
of adjuvant treatment, unjustified dose reductions of 
cytotoxic drugs (e.g. in obese patients [12]) are unfavour-
able in terms of the probability of response and patient 
prognosis, and they should be considered primarily if 
unacceptable tolerance of treatment occurs.
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